All the news Showing 6 of 86 articles from: Treatment for people living with HIV and HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis C drug boceprevir achieves 70% viral suppression rate in HIV co-infected people within 24 weeks Gus Cairns / 22 October 2011 Interim results presented at the Infectious Diseases Society of America (IDSA) conference yesterday show that 70.5% of 98 patients with HIV and hepatitis C who took the hepatitis C protease inhibitor (PI) drug ... New European HIV treatment guidelines expand treatment recommendations but anticipate possible drug shortages Gus Cairns / 18 October 2011 The new edition of the European AIDS Clinical Society (EACS) treatment guidelines for people with HIV was published last week at the 13th European AIDS Conference in Belgrade, Serbia. ... Genetic variation associated with response to hepatitis C therapy in HIV co-infected patients Michael Carter / 05 May 2011 The presence of a genetic variation in the IL28B gene is associated with better response rates to hepatitis C therapy in patients who are co-infected with HIV and hepatitis C, Spanish investigators ... HIV treatment preserves CD4 cell count during and after HCV therapy in co-infected patients Michael Carter / 03 May 2011 Antiretroviral therapy helps preserve the CD4 cell counts of HIV-positive patients undergoing treatment for hepatitis C, Austrian investigators report in the June 15th edition of the Journal of Infectious Diseases. Treatment with ... Good survival rates for HIV/HCV-coinfected patients with compensated cirrhosis Michael Carter / 14 March 2011 Medium-term survival rates in patients co-infected with HIV and hepatitis C who have compensated cirrhosis are good and comparable to those seen in hepatitis C-mono-infected individuals, Spanish investigators report in the online edition ... Telaprevir works well for people with HIV/HCV co-infection Liz Highleyman / 02 March 2011 The experimental hepatitis C virus (HCV) protease inhibitor telaprevir, used with pegylated interferon plus ribavirin, produced good virological response in the first study of HIV/HCV co-infected individuals, according to interim data presented on Wednesday ... ← Prev1...56789Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive